Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Matas, Elisabet ^a   Bau, Laura ^a   Martínez Iniesta, María ^b   Romero Pinel, Lucía ^a   Alba Mane M ^a,c   Cobo Calvo, Älvaro ^a   Martínez Yélamos, Sergio ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; BETA INTERFERON; BIOLOGICAL MARKER; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MULTIPLE SCLEROSIS; MXA GENE; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL;

BIOMARKERS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; MYXOVIRUS RESISTANCE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS;

EID: 84911936808     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112758     Document Type: Article

References (28)

1. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43: 655-661.
2. Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind placebo controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Group. Neurology 43: 662-667.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285-294.
4. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, et al. (1997) Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 49: 358-363.
5. PRIMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504.
6. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56: 1628-1636.
7. Malucchi S, Gili F, Caldano M, Marnetto F, Valentino P, et al. (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70: 1119-1127.
8. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
9. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33: 1444-52.
10. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55: 671-676.
11. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, et al. (1965) Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 122: 552-558.
12. Río J, Nos C, Tintoré M, Borrás C, Galán I, et al. (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52: 400-406.
13. Bertolotto A, Gilli F, Sala A, Audano L, Castello A, et al. (2001) Evaluation of bioavailability of three types of IFNb in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256: 141-152.
14. Hesse S, Sellebjerg F, Sorensen PS (2009) Absence of MxA induction by interferon b in patients with MS reflects complete loss of bioactivity. Neurology 73: 372-377.
15. Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, et al. (2011) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 258: 895-903.
16. Sominada A, Hillert J, Fogdell-Hahn A (2008) In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralizing antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 79: 57-62.
17. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56: 548-555.
18. Verweij CL, Vosslamber S (2013) Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov Med 15: 51-60.
19. Comabella M, Lünemann JD, Rio J, Sánchez A, López C, et al. (2009) A type I interferon signature in monocytes is associated with poor response to interferon-B in multiple sclerosis. Brain 132: 3353-3365.
20. van Baarsen L, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, et al. (2008) Pharmacogenomics of interferon-B therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLos One 3(4): e1927. Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001927 Accessed April 02, 2008.
21. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, et al. (2010) T helper type I and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16: 406-412.
22. Hundeshagen A, Hecker M, Paap BK, Angerstein C, Kandulski O, et al. (2012) Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflammation 9: 140. Available: http://www.jneuroinflammation.com/content/9/1/140 Accessed 22 June 2012.
23. Sottini A, Capra R, Serana, Chiarini M, Caimi L, et al. (2009) Interferon-Beta therapy monitoring in multiple sclerosis patients. Edcr Metab Immune Disord Drug Targets 9: 14-28.
24. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, et al. (2002) Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 129: 205-215.
25. Hesse D, Krakauer M, Lund H, Ryder LP, Alsing I, et al. (2007) Spontaneous MxA mRNA expression is associated with low MRI disease activity in multiple sclerosis. Mult Scler 13: S37-S38, p143.
26. Van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, et al. (2010) Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology 75: 1228-1233.
27. Serana F, Imberti L, Amato MP, Comi G, Gasperini C, et al. (2014) MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. PLoS One 9(4): e94794. Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0094794. Accessed 2014 Apr 14.
28. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, et al. (2007) Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13: 208-214.